Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | RECQL | P46063 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.40 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 3/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | GRM5 | P41594 | 3/20 | 0.38 |
| ▸ | KCNJ1 | P48048 | 1/20 | 0.36 |
| ▸ | PARP1 | P09874 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18368411 | 0.83 | KCNJ1 (0.38) | POLBRECQLLMNAALDH1A1SMN1; SMN2 | |
| SCHEMBL5810873 | 0.81 | HTT (0.43) | LMNAALDH1A1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL5809501 | 0.80 | HTT (0.54) | POLBLMNAALDH1A1SMN1; SMN2MEN1 | |
| SCHEMBL5808991 | 0.80 | GRM5 (0.39) | HTTGRM5KCNJ1 | |
| SCHEMBL5806592 | 0.79 | ALDH1A1 (0.49) | LMNAALDH1A1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL1710145 | 0.78 | MEN1 (0.38) | LMNAALDH1A1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL12090844 | 0.78 | POLB (0.51) | POLBRECQLLMNAALDH1A1SMN1; SMN2 | |
| SCHEMBL5810628 | 0.78 | DRD2 (0.43) | POLBRECQLLMNAALDH1A1SMN1; SMN2 | |
| SCHEMBL5839596 | 0.77 | HTT (0.35) | POLBRECQLMEN1KMT2AHTT | |
| SCHEMBL23952507 | 0.77 | POLB (0.50) | POLBRECQLLMNAALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7144894-B2 | Sulfonamide bicyclic compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-12-05 | — | — | US | disclosed |
| WO-2006034480-A2 | SULFONAMIDE BICYCLIC COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-03-30 | — | — | WO | disclosed |
| US-20060063799-A1 | Sulfonamide bicyclic compounds | BRISTOL-MYERS SQUIBB COMPANY | 2006-03-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060063799-A1 | Sulfonamide bicyclic compounds | APP, BACE1, IAPP | POLB 3416/4885RECQL 4542/4885LMNA 1675/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.